Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC) and Neurocrine (NBIX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenet Healthcare (THC – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tenet Healthcare (THC)
In a report released yesterday, Sarah James from Cantor Fitzgerald reiterated a Buy rating on Tenet Healthcare, with a price target of $245.00. The company’s shares closed last Wednesday at $226.35.
According to TipRanks.com, James is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenet Healthcare with a $249.17 average price target, which is a 32.3% upside from current levels. In a report issued on February 2, UBS also maintained a Buy rating on the stock with a $260.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Neurocrine yesterday and set a price target of $170.00. The company’s shares closed last Wednesday at $137.44.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $181.88, which is a 32.8% upside from current levels. In a report issued on January 28, TipRanks – xAI also upgraded the stock to Buy with a $152.00 price target.
